Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07211776) titled 'A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease' on Oct. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Zai Lab (Shanghai) Co., Ltd.
Condition:
Thyroid Eye Disease (TED)
Intervention:
Drug: ZL-1109 (VRDN-003)
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: December 27, 2025
Target Sample Size: 99
Countries of Recruitment:
China
To know more, visi...